BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to SW780 cell line is 171
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MAGEA3 | 6801 | LTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | SP assay followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0021 | 25031712 |
| SOX4 | 11200 | LTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | Western Blotting | NA | 0.28 | 0.0042 | 26681916 |
| ABCB1 | 40 | LTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | SP assay followed by CFA and RT-PCR | NA | 0.2 | 0.0604 | 18787416 |
| ABCG2 | 74 | LTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | SP assay followed by CFA and RT-PCR | NA | 0.2 | 0.1739 | 18787416 |
| ABCG2 | 74 | LTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | SP assay followed by RT-PCR and SFA | NA | 0.2 | 0.1739 | 25031712 |
| BMI1 | 1066 | LTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | SP assay followed by CFA and RT-PCR | NA | 0.2 | 0.1135 | 18787416 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | SP assay followed by CFA and RT-PCR | NA | 0.2 | 0.6448 | 18787416 |
| PROM1 | 9454 | LTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | SP assay followed by RT-PCR and SFA | NA | 0.2 | 0.7582 | 25031712 |
| CD44 | 1681 | LTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs | NA | 0.12 | 1 | 25748177 |
| CD44 | 1681 | LTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs | NA | 0.12 | 1 | 29340052 |
| CD44 | 1681 | LTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | SFA followed by FACs | NA | 0.12 | 1 | 23226620 |
| ITGA6 | 6142 | LTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs | NA | 0.12 | 0.0265 | 25748177 |
| ITGA6 | 6142 | LTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | SFA followed by FACs | NA | 0.12 | 0.0265 | 23226620 |
| OV6 | NA | LTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | SFA followed by FACs | NA | 0.12 | 0.0011 | 30397177 |
| ABCE1 | 69 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| ACTN4 | 166 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0074 | 29340052 |
| ADAM7 | 214 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| ADAMTS14 | 14899 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| ADTRP | 21214 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| AEBP2 | 24051 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| ALG3 | 23056 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| ANK1 | 492 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| ANKRD13A | 21268 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| ANKRD28 | 29024 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| ARL13B | 25419 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| ASB11 | 17186 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| ATF3 | 785 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| ATP6V1G2 | 862 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| ATP8B4 | 13536 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| AZIN1 | 16432 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| BCHE | 983 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| BCL2L14 | 16657 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| BCLAF1 | 16863 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| BEST3 | 17105 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| C1orf9 | 1240 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| C1QTNF7 | 14342 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| CACYBP | 30423 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| CAPRIN2 | 21259 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| CARM1 | 23393 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| CASC4 | 24892 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| CASP3 | 1504 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| CCDC43 | 26472 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| CD99L2 | 18237 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29340052 |
| CDCA7L | 30777 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| CDH2 | 1759 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0085 | 29340052 |
| CEP152 | 29298 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| CEP55 | 1161 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| CLPTM1 | 2087 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| CLU | 2095 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0064 | 29340052 |
| CNKSR3 | 23034 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| CNOT3 | 7879 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| CNR1 | 2159 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| COP1 | 17440 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| CRISPLD1 | 18206 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| CT45A2 | 28400 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| CTNNA1 | 2509 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| CTNNB1 | 2514 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0647 | 29340052 |
| DGCR8 | 2847 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| DHX9 | 2750 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 29340052 |
| DIS3 | 20604 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| DIS3L2 | 28648 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| DMTN | 3382 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| DNAJC14 | 24581 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| EDEM3 | 16787 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| ERBIN | 15842 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| F3 | 3541 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| FAM104B | 25085 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| FAM3D | 18665 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| FKBP5 | 3721 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29340052 |
| FLII | 3750 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| GART | 4163 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0064 | 29340052 |
| GAS7 | 4169 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| GK2 | 4291 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| GLYAT | 13734 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| HAUS6 | 25948 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| HAVCR1 | 17866 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| HEPHL1 | 30477 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| HERC6 | 26072 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| HMCN1 | 19194 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| HMMR | 5012 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| HOXC4 | 5126 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| HPGD | 5154 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| ICAM2 | 5345 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| IL4 | 6014 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| IMPA1 | 6050 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| INO80D | 25997 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| INTS14 | 25372 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| ITGB1 | 6153 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.018 | 29340052 |
| ITSN2 | 6184 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| KCNIP1 | 15521 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| KIF27 | 18632 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| LCK | 6524 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| LEXM | 26854 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| LIMA1 | 24636 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| LNX2 | 20421 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| LRRCC1 | 29373 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| MAGEA12 | 6799 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| MAGED2 | 16353 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| MAP3K21 | 29798 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| MB21D2 | 30438 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| MED14 | 2370 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| MOCS1 | 7190 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| MS4A2 | 7316 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| MT1M | 14296 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| MYC | 7553 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.1304 | 29340052 |
| MYO5B | 7603 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| NAA16 | 26164 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| NANOS1 | 23044 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| NCALD | 7655 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| NCAPD3 | 28952 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| NCAPG | 24304 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| NEK7 | 13386 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| NLRP7 | 22947 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| NONO | 7871 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| NOS1AP | 16859 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| NPRL3 | 14124 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| NXF2 | 8072 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| OGN | 8126 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| OPA1 | 8140 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| OR4C16 | 15172 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| OR8J1 | 14855 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| P2RX5 | 8536 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| PAEP | 8573 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| PHF6 | 18145 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| PIK3R1 | 8979 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| PKP2 | 9024 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| PLAGL1 | 9046 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| PPIP5K2 | 29035 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| PRMT3 | 30163 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| PRR15L | 28149 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| PRRG1 | 9469 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| RANBP17 | 14428 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| RBM12 | 9898 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| RBP2 | 9920 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| RECQL | 9948 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| RFLNA | 27051 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| RGS8 | 16810 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| RNF41 | 18401 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| S1PR5 | 14299 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| SART1 | 10538 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| SCML1 | 10580 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| SEPTIN7 | 1717 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| SF3B1 | 10768 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| SLC16A3 | 10924 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| SLC18A2 | 10935 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| SLC39A6 | 18607 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| SLC6A8 | 11055 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| SPAST | 11233 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| SSX2IP | 16509 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| STEAP1B | 41907 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| STK26 | 18174 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| SYPL1 | 11507 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| SYT5 | 11513 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| TAS2R41 | 18883 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| TBR1 | 11590 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| TBX5 | 11604 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| TCHP | 28135 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| TEDC1 | 20127 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| TMEM155 | 55077 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| TNIP3 | 19315 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| TRIM5 | 16276 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| TRIQK | 27828 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| UBE3A | 12496 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| UCHL1 | 12513 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| UHRF1 | 12556 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| WEE2 | 19684 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| XPO5 | 17675 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| ZBTB11 | 16740 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| ZNF146 | 12931 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| ZNF512 | 29380 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| ZNF614 | 24722 | HTM | Bladder Cancer | Transitional Cell Carcinoma | SW780 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |